High performance plasma amyloid-β biomarkers for Alzheimer's disease
The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Abstract
To facilitate clinical trials of disease-modifying therapies for Alzheimer's disease, which are expected to be most efficacious at the earliest and mildest stages of the disease, supportive biomarker information is necessary. The only validated methods for identifying amyloid-β deposition in the brain-the earliest pathological signature of Alzheimer's disease-are amyloid-β positron-emission tomography (PET) imaging or measurement of amyloid-β in cerebrospinal fluid. Therefore, a minimally invasive, cost-effective blood-based biomarker is desirable. Despite much effort, to our knowledge, no study has validated the clinical utility of blood-based amyloid-β markers. Here we demonstrate the measurement of high-performance plasma amyloid-β biomarkers by immunoprecipitation coupled with mass spectrometry. The ability of amyloid-β precursor protein (APP) 669-711 /amyloid-β (Aβ) 1-42 and Aβ 1-40 /Aβ 1-42 ratios, and their composites, to predict individual brain amyloid-β-positive or -negative status was determined by amyloid-β-PET imaging and tested using two independent data sets: a discovery data set (Japan, n = 121) and a validation data set (Australia, n = 252 including 111 individuals diagnosed using 11 C-labelled Pittsburgh compound-B (PIB)-PET and 141 using other ligands). Both data sets included cognitively normal individuals, individuals with mild cognitive impairment and individuals with Alzheimer's disease. All test biomarkers showed high performance when predicting brain…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The ratio of plasma Aβ42:Aβ40 using a high precision assay has a high correlation with amyloid PET. (450, 451)”
From Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission (2024) · cites this paper as [451]
In the citing paper
“Plasma p-tau181, p-tau217, and p-tau231 have a good or better accuracy than amyloid CSF Abeta and tau and PET measures of tau and amyloid pathology in discriminating people with amyloid pathology who may have clinical symptoms.(452-454)”
From Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission (2024) · cites this paper as [452]
In the citing paper
“The results demonstrated, with very high confidence (over 94% of samples tested), that amyloid β-biomarkers in plasma can correctly discriminate among control, aMCI, and AD subjects.”
From Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease (2019) · cites this paper as [68]
In the citing paper
“Amyloid imaging detects amyloid in the brain with high sensitivity and specificity in both cognitively normal and people with Alzheimer's disease when the gold-standard comparison is either neuropathology or clinical diagnosis, distinguishing Alzheimer's disease from other neurodegenerative conditions.183”
From Dementia prevention, intervention, and care: 2020 report of the Lancet Commission (2020) · cites this paper as [183]
In the citing paper
“In clinical practice, it happens that the biomarkers change to contrary directions, which raises difficulties for clinicians to draw conclusions5,51.”
From Integrated algorithm combining plasma biomarkers and cognitive assessments accurately predicts brain β-amyloid pathology (2023) · cites this paper as [51]
9 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
An analysis of variance test for normality (complete samples)
SHAPIRO, S. S., & WILK, M. B. (1965) · Biometrika · doi:10.1093/biomet/52.3-4.591 · Cited by 23,480
DeLong, E. R., DeLong, D. M., & Clarke-Pearson, D. L. (1988) · Biometrics · doi:10.2307/2531595 · Cited by 22,649
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
Albert, M. S., DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., Gamst, A., Holtzman, D. M., Jagust, W. J., Petersen, R. C., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.008 · Cited by 10,152
Pencina, M. J., D' Agostino, R. B., D' Agostino, R. B., & Vasan, R. S. (2008) · Statistics in Medicine · doi:10.1002/sim.2929 · Cited by 6,493
The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., et al. (2016) · Nature · doi:10.1038/nature19323 · Cited by 3,059
Albert, M. S., DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., Gamst, A., Holtzman, D. M., Jagust, W. J., Petersen, R. C., et al. (2013) · Focus · doi:10.1176/appi.focus.11.1.96 · Cited by 2,621
Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects
Shaw, L. M., Vanderstichele, H., Knapik‐Czajka, M., Clark, C. M., Aisen, P. S., Petersen, R. C., Blennow, K., Soares, H., Simon, A., Lewczuk, P., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21610 · Cited by 2,065
Use of Florbetapir-PET for Imaging β-Amyloid Pathology
Clark, C. M. (2011) · JAMA · doi:10.1001/jama.2010.2008 · Cited by 1,117
Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging
Rowe, C. C., Ellis, K. A., Rimajova, M., Bourgeat, P., Pike, K. E., Jones, G., Fripp, J., Tochon-Danguy, H., Morandeau, L., O'Keefe, G., et al. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.04.007 · Cited by 986
Self-citationEllis, K. A., Bush, A. I., Darby, D., De Fazio, D., Foster, J., Hudson, P., Lautenschlager, N. T., Lenzo, N., Martins, R. N., Maruff, P., et al. (2009) · International Psychogeriatrics · doi:10.1017/s1041610209009405 · Cited by 968
Self-citationA systemic view of Alzheimer disease — insights from amyloid-β metabolism beyond the brain
Wang, J., Gu, B. J., Masters, C. L., & Wang, Y.-J. (2017) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.111 · Cited by 808
Self-citationThe Evolution of Preclinical Alzheimer’s Disease: Implications for Prevention Trials
Sperling, R., Mormino, E., & Johnson, K. (2014) · Neuron · doi:10.1016/j.neuron.2014.10.038 · Cited by 725
Wong, D. F., Rosenberg, P. B., Zhou, Y., Kumar, A., Raymont, V., Ravert, H. T., Dannals, R. F., Nandi, A., Brašić, J. R., Ye, W., et al. (2010) · Journal of Nuclear Medicine · doi:10.2967/jnumed.109.069088 · Cited by 684
18F‐flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: A phase 2 trial
Vandenberghe, R., Van Laere, K., Ivanoiu, A., Salmon, E., Bastin, C., Triau, E., Hasselbalch, S., Law, I., Andersen, A., Korner, A., et al. (2010) · Annals of Neurology · doi:10.1002/ana.22068 · Cited by 646
Plasma β-amyloid in Alzheimer's disease and vascular disease
Janelidze, S., Stomrud, E., Palmqvist, S., Zetterberg, H., van Westen, D., Jeromin, A., Song, L., Hanlon, D., Tan Hehir, C. A., Baker, D., et al. (2016) · Scientific Reports · doi:10.1038/srep26801 · Cited by 626
Ovod, V., Ramsey, K. N., Mawuenyega, K. G., Bollinger, J. G., Hicks, T., Schneider, T., Sullivan, M., Paumier, K., Holtzman, D. M., Morris, J. C., et al. (2017) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2017.06.2266 · Cited by 585
Relationships between biomarkers in aging and dementia
Jagust, W. J., Landau, S. M., Shaw, L. M., Trojanowski, J. Q., Koeppe, R. A., Reiman, E. M., Foster, N. L., Petersen, R. C., Weiner, M. W., Price, J. C., et al. (2009) · Neurology · doi:10.1212/wnl.0b013e3181bc010c · Cited by 456
CSF biomarker variability in the Alzheimer's Association quality control program
Mattsson, N., Andreasson, U., Persson, S., Carrillo, M. C., Collins, S., Chalbot, S., Cutler, N., Dufour‐Rainfray, D., Fagan, A. M., Heegaard, N. H. H., et al. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.01.010 · Cited by 382
Self-citationThe future of blood‐based biomarkers for Alzheimer's disease
Henriksen, K., O'Bryant, S. E., Hampel, H., Trojanowski, J. Q., Montine, T. J., Jeromin, A., Blennow, K., Lönneborg, A., Wyss‐Coray, T., Soares, H., et al. (2014) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.01.013 · Cited by 313
O'Bryant, S. E., Mielke, M. M., Rissman, R. A., Lista, S., Vanderstichele, H., Zetterberg, H., Lewczuk, P., Posner, H., Hall, J., Johnson, L., et al. (2017) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.09.014 · Cited by 303
Self-citationAmyloid PET imaging in Alzheimer’s disease: a comparison of three radiotracers
Initiative, T. A. D. N., Landau, S. M., Thomas, B. A., Thurfjell, L., Schmidt, M., Margolin, R., Mintun, M., Pontecorvo, M., Baker, S. L., & Jagust, W. J. (2014) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-014-2753-3 · Cited by 294
Amyloid and APOE ε4 interact to influence short-term decline in preclinical Alzheimer disease
Mormino, E. C., Betensky, R. A., Hedden, T., Schultz, A. P., Ward, A., Huijbers, W., Rentz, D. M., Johnson, K. A., Sperling, R. A., & For the Alzheimer's Disease Neuroimaging Initiative, T. A. I. B. A. L. F. S. O. A. (2014) · Neurology · doi:10.1212/wnl.0000000000000431 · Cited by 293
O'Bryant, S. E., Gupta, V., Henriksen, K., Edwards, M., Jeromin, A., Lista, S., Bazenet, C., Soares, H., Lovestone, S., Hampel, H., et al. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.08.099 · Cited by 290
Self-citationThe C‐Terminus of the β Protein is Critical in Amyloidogenesisa
JARRETT, J. T., BERGER, E. P., & LANSBURY, P. T. (1993) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1993.tb23043.x · Cited by 260
Age and amyloid effects on human central nervous system amyloid‐beta kinetics
Patterson, B. W., Elbert, D. L., Mawuenyega, K. G., Kasten, T., Ovod, V., Ma, S., Xiong, C., Chott, R., Yarasheski, K., Sigurdson, W., et al. (2015) · Annals of Neurology · doi:10.1002/ana.24454 · Cited by 200
Fagan, A. M., Shaw, L. M., Xiong, C., Vanderstichele, H., Mintun, M. A., Trojanowski, J. Q., Coart, E., Morris, J. C., & Holtzman, D. M. (2011) · Archives of Neurology · doi:10.1001/archneurol.2011.105 · Cited by 189
Novel plasma biomarker surrogating cerebral amyloid deposition
KANEKO, N., Nakamura, A., Washimi, Y., Kato, T., Sakurai, T., Arahata, Y., Bundo, M., Takeda, A., Niida, S., Ito, K., et al. (2014) · Proceedings of the Japan Academy Series B · doi:10.2183/pjab.90.353 · Cited by 146
Self-citationChanges in plasma amyloid beta in a longitudinal study of aging and Alzheimer's disease
Rembach, A., Faux, N. G., Watt, A. D., Pertile, K. K., Rumble, R. L., Trounson, B. O., Fowler, C. J., Roberts, B. R., Perez, K. A., Li, Q., et al. (2013) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2012.12.006 · Cited by 142
Self-citationComparison of MR-less PiB SUVR quantification methods
Bourgeat, P., Villemagne, V. L., Doré, V., Brown, B. M., Macaulay, S. L., Martins, R. N., Masters, C. L., Ames, D. J., Ellis, K. A., Rowe, C. C., et al. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.04.033 · Cited by 138
Self-citationLundqvist, R., Lilja, J., Thomas, B. A., Lötjönen, J. M. P., Villemagne, V. L., Rowe, C. C., & Thurfjell, L. (2013) · Journal of Nuclear Medicine · doi:10.2967/jnumed.112.115006 · Cited by 117
Self-citationIrwin, D. J., McMillan, C. T., Toledo, J. B., Arnold, S. E., Shaw, L. M., Wang, L.-S., Van Deerlin, V., Lee, V. M.-Y., Trojanowski, J. Q., & Grossman, M. (2012) · Archives of Neurology · doi:10.1001/archneurol.2012.26 · Cited by 116
Pannee, J., Portelius, E., Oppermann, M., Atkins, A., Hornshaw, M., Zegers, I., Höjrup, P., Minthon, L., Hansson, O., Zetterberg, H., et al. (2013) · Journal of Alzheimer’s Disease · doi:10.3233/jad-2012-121471 · Cited by 105
Boccardi, M., Altomare, D., Ferrari, C., Festari, C., Guerra, U. P., Paghera, B., Pizzocaro, C., Lussignoli, G., Geroldi, C., Zanetti, O. O., et al. (2016) · JAMA Neurology · doi:10.1001/jamaneurol.2016.3751 · Cited by 98
Plasma concentrations of free amyloid β cannot predict the development of Alzheimer's disease
Lövheim, H., Elgh, F., Johansson, A. S., Zetterberg, H., Blennow, K., Hallmans, G., & Eriksson, S. (2017) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2016.12.004 · Cited by 93
Schlenzig, D., Rönicke, R., Cynis, H., Ludwig, H., Scheel, E., Reymann, K. G., Saido, T. C., Hause, G., Schilling, S., & Demuth, H. (2012) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2012.07707.x · Cited by 83
Li, Q., Villemagne, V. L., Doecke, J. D., Rembach, A., Sarros, S., Varghese, S., McGlade, A. R., Laughton, K. M., Pertile, K. K., Fowler, C. J., et al. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-150247 · Cited by 77
Self-citationKANEKO, N., Yamamoto, R., Sato, T., & Tanaka, K. (2014) · Proceedings of the Japan Academy Series B · doi:10.2183/pjab.90.104 · Cited by 75
Self-citationMass++: A Visualization and Analysis Tool for Mass Spectrometry
Tanaka, S., Fujita, Y., Parry, H. E., Yoshizawa, A. C., Morimoto, K., Murase, M., Yamada, Y., Yao, J., Utsunomiya, S.-I., Kajihara, S., et al. (2014) · Journal of Proteome Research · doi:10.1021/pr500155z · Cited by 53
Self-citationAssociation of plasma and cortical amyloid beta is modulated by APOE ε4 status
Swaminathan, S., Risacher, S. L., Yoder, K. K., West, J. D., Shen, L., Kim, S., Inlow, M. H., Foroud, T., Jagust, W., Koeppe, R. A., et al. (2013) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2013.01.007 · Cited by 49
Amyloid-beta 42 adsorption following serial tube transfer
Toombs, J., Paterson, R. W., Schott, J. M., & Zetterberg, H. (2014) · Alzheimer s Research & Therapy · doi:10.1186/alzrt236 · Cited by 49
Rembach, A., the AIBL Research Group, Watt, A. D., Wilson, W. J., Villemagne, V. L., Burnham, S. C., Ellis, K. A., Maruff, P., Ames, D., Rowe, C. C., et al. (2014) · Journal of Alzheimer's Disease · doi:10.3233/jad-131802 · Cited by 48
Self-citationGelfanova, V., Higgs, R. E., Dean, R. A., Holtzman, D. M., Farlow, M. R., Siemers, E., Boodhoo, A., Qian, Y., He, X., Jin, Z., et al. (2007) · Briefings in Functional Genomics and Proteomics · doi:10.1093/bfgp/elm010 · Cited by 47
Villemagne, V. L. (2014) · Advances in Research · doi:10.9734/air/2014/11599 · Cited by 43
Self-citationOvercoming synthetic Aβ peptide aging: a new approach to an age-old problem
Manzoni, C., Colombo, L., Messa, M., Cagnotto, A., Cantú, L., Favero, E. D., & Salmona, M. (2009) · Amyloid · doi:10.1080/13506120902879848 · Cited by 39
Clinical Impact of Amyloid Positron Emission Tomography—Is It Worth the Cost?
Caselli, R. J., & Woodruff, B. K. (2016) · JAMA Neurology · doi:10.1001/jamaneurol.2016.3792 · Cited by 10
(1950) · doi:10.1002/1097-0142(1950)3:1<32::aid-cncr2820030106>3.0.co;2-3
Research works printed but not linked: 1
- Rogers, M. B. Are CSF Assays Finally Ready for Prime Time? Alzforum https://www.alzforum.org/news/conference-coverage/are-csf-assays-finally-ready-prime-time (2017)
Cited by
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.018 · Cited by 10,537
“Plasma Aβ measures now show promise [202,203].”
Self-citationDementia prevention, intervention, and care: 2020 report of the Lancet Commission
Livingston, G., Huntley, J., Sommerlad, A., Ames, D., Ballard, C., Banerjee, S., Brayne, C., Burns, A., Cohen-Mansfield, J., Cooper, C., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30367-6 · Cited by 10,430
RetractedDementia prevention, intervention, and care: 2024 report of the Lancet standing Commission
Livingston, G., Huntley, J., Liu, K. Y., Costafreda, S. G., Selbæk, G., Alladi, S., Ames, D., Banerjee, S., Burns, A., Brayne, C., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01296-0 · Cited by 3,860
Alzheimer Disease: An Update on Pathobiology and Treatment Strategies
Long, J. M., & Holtzman, D. M. (2019) · Cell · doi:10.1016/j.cell.2019.09.001 · Cited by 3,204
Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup
Jack, C. R., Andrews, J. S., Beach, T. G., Buracchio, T., Dunn, B., Graf, A., Hansson, O., Ho, C., Jagust, W., McDade, E., et al. (2024) · Alzheimer's & Dementia · doi:10.1002/alz.13859 · Cited by 2,803
Metadata
- Authors
- Nakamura, A., Kaneko, N., Villemagne, V. L., Kato, T., Doecke, J., Doré, V., Fowler, C., Li, Q.-X., Martins, R., Rowe, C., Tomita, T., Matsuzaki, K., Ishii, K., Ishii, K., Arahata, Y., Iwamoto, S., Ito, K., Tanaka, K., Masters, C. L., & Yanagisawa, K.
- Affiliations
- National Center for Geriatrics and Gerontology (JP)
- Shimadzu (Japan) (JP)
- The University of Melbourne (AU)
- Commonwealth Scientific and Industrial Research Organisation (AU)
- Edith Cowan University (AU)
- The University of Tokyo (JP)
- Kyoto University (JP)
- Tokyo Metropolitan Institute of Gerontology (JP)
- National Hospital for Geriatric Medicine, National Center for Geriatrics and Gerontology (JP)
- Corresponding author
- Yanagisawa, Katsuhiko
- ORCID
- Venue
- Nature
- Published
- 2018-01-31
- Volume
- 554
- Issue
- 7691
- Pages
- 249-254
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2785757836
- Cited by
- 1,681
- References
- 47
- Citations by year
- 2026: 137 · 2025: 166 · 2024: 204 · 2023: 203 · 2022: 227 · 2021: 233 · 2020: 236 · 2019: 174 · 2018: 97
- FWCI
- 127.20
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Research Online (Edith Cowan University) (submittedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Center for Geriatrics and Gerontology
- Japan Society for the Promotion of Science (15H02492)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Physical Sciences › Chemistry › Spectroscopy › Mass Spectrometry Techniques and Applications
- Keywords
- Alzheimer's disease, amyloid-beta deposition, blood-based biomarkers, immunoprecipitation mass spectrometry, 11C-Pittsburgh compound B, cerebrospinal fluid amyloid-beta
- MeSH terms
- Aged, Alzheimer Disease, Australia, Brain, Cost-Benefit Analysis, Female, Humans, Japan, Male, Peptide Fragments, Mass Spectrometry, Reproducibility of Results, Biomarkers, Case-Control Studies, Amyloid beta-Peptides, Amyloid beta-Protein Precursor, Immunoprecipitation, Positron-Emission Tomography, Cognitive Dysfunction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.